cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Gilead Sciences Inc
158 own
150 watching
Current Price
$83.73
$0.11
(0.13%)
logo-gild
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
104,997.42M
52-Week High
52-Week High
89.74
52-Week Low
52-Week Low
57.165
Average Volume
Average Volume
4.11M
Dividend Yield
Dividend Yield
0.04237
P/E Ratio
P/E Ratio
11.3194
iconMarket Capitalization104,997.42M
icon52-Week High89.74
icon52-Week Low57.165
iconAverage Volume4.11M
iconDividend Yield0.04237
iconP/E Ratio11.3194
What does the Gilead Sciences Inc do?
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company's products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis C virus and hepatitis B virus; hematology/oncology; cardiovascular; and inflammation/respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.
Read More
How much money does Gilead Sciences Inc make?
News & Events about Gilead Sciences Inc.
Zolmax
8days ago
Gilead Sciences (NASDAQ:GILD Get Rating) had its target price raised by Piper Sandler from $104.00 to $111.00 in a research report sent to investors on Thursday morning, The Fly reports. Piper Sandler currently has an overweight rating on the biopharmaceutical companys stock. A number of other ...
Benzinga
11days ago
Latest Ratings for GILD DateFirmActionFromTo Mar 2022BarclaysMaintainsUnderweight Mar 2022RBC CapitalMaintainsOutperform Feb 2022BMO CapitalDowngradesOutperformMarket Perform View More Analyst Ratings for GILD View the Latest Analyst Ratings read more...
Accesswire
11days ago
NORTHAMPTON, MA / ACCESSWIRE / January 19, 2023 / Dr. Hila Elinav burst into tears of joy when the Israeli Ministry of Health announced a sweeping new HIV screening policy for pregnant women in September.'It was a long-awaited, emotional moment,' says Hila, a member of the Israeli...
Stock Options Channel
12days ago
Investors in Gilead Sciences Inc (GILD) saw new options begin trading today, for the April 21st expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 93 days until expiration the newly trading contracts represent a possible ...
Accesswire
18days ago
NORTHAMPTON, MA / ACCESSWIRE / January 12, 2023 / Gilead Sciences Every time a serious new COVID-19 virus variant emerges, Gilead virologists Charlotte Hedskog and John Bilello, alongside their teams, mobilize as so-called 'variant hunters.'Their mission is to determine whether...
Frequently Asked Questions
Frequently Asked Questions
What is Gilead Sciences Inc share price today?
plus_minus_icon
Can Indians buy Gilead Sciences Inc shares?
plus_minus_icon
How can I buy Gilead Sciences Inc shares from India?
plus_minus_icon
Can Fractional shares of Gilead Sciences Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Gilead Sciences Inc stocks?
plus_minus_icon
What is today’s traded volume of Gilead Sciences Inc?
plus_minus_icon
What is today’s market capitalisation of Gilead Sciences Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Gilead Sciences Inc?
plus_minus_icon
What percentage is Gilead Sciences Inc down from its 52-Week High?
plus_minus_icon
What percentage is Gilead Sciences Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$83.73
$0.11
(0.13%)
logo-gild
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00